Reactogenicity and immunogenicity of combined haemophilus influenzae type B-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccinehib-menc-TT booster with routine MMR vaccine

Pediatric Infectious Disease Journal

Volumn 29, Issue 3, 2010, Pages 269-271

  Carmona, Alfonso ^a   Miranda, Mariano ^b   Barrio, Francisco ^c   De Vicente, Ana ^d   Mares, Josep ^e   Muñoz, Eulalia ^f   Diez Delgado, Javier ^g   Alonso, Angeles ^h   Giménez Sánchez, Francisco ⁱ   Merino, José ^j   García Corbeira, Pilar ^k   Maechler, Gudrun ^l   Boutriau, Dominique ^l  

^a Instituto Hispalense de Pediatria   (Spain)

^b Hospital Antequera   (Spain)

^c Especialidad en Oftalmología Hospital Comarcal de la Axarquía Vélez Málaga Málaga   (Spain)

^d Clínica Sanimed   (Spain)

^e Institut Pediatric Marés   (Spain)

^f Centro de Salud Dr Castroviejo   (Spain)

^g HOSPITAL TORRECÁRDENAS   (Spain)

^h La Zarzuela Hospital ^*  (Spain)

ⁱ Mediterranea Medica Clinic   (Spain)

^j HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^k GLAXOSMITHKLINE   (Spain)

^l GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

more..

Author keywords

Hib MenC TT; MenC CRM197; MMR; Neisseria meningitidis; Toddlers

Indexed keywords

BACTERIAL VACCINE; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS SEROGROUP C CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENITORIX; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MASTOIDITIS; MEASLES; MUMPS; PERIANAL ABSCESS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUBELLA; TODDLER;

EID: 77649202331     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181c15977     Document Type: Article

References (13)

1. Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines. 2006;5: 851-857.
2. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367.
3. Schmitt HJ, Maechler G, Habermehl P, et al. Immunogenicity, reactoge-nicity and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vac Immunol. 2007;14:426-434.
4. Tejedor JC, Moro M, Ruiz-Contreras J, et al; for the Spanish DTPa-HBV-IPV-097 Study Group. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inac-tivated poliovirus vaccine at 2, 4 and 6 months. Pediatr Infect Dis J. 2007;26:1-7.
5. Snape D, Pace D, Westcar S, et al. Immunogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid booster vaccine at age 12 months [abstract]. Paper presented at: 25th Annual meeting of the European Society for Paediatric Infectious Diseases-ESPID; May 2-5, 2007; Madrid.
6. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227.
7. Virtanen M, Peltola H, Paunio M, et al. Day-to-day reactogenicity and the healthy vaccine effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106:E62.
8. Ministerio de Sanidad y Consumo. Calendarios de Vacunacion Recomendados 2004. Available at: http://tuotromedico.com/temas/calendario-vacunal.htm#3. Accessed June 13, 2007.
9. Tejedor JC, Moro M, Merino JM, et al; for the Spanish 102547 Study Group. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J. 2008;27:579-588.
10. Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J. 2001;20: S23-S29.
11. Pace D, Snape M, Westcar S, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child. 2008;93:963-970.
12. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163.
13. Tejedor JC, Omenaca F, García-Sicilia J, et al. Spanish DTPa-IPV/Hib-049 Study Group. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine co-administered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age. Pediatr Infect Dis J. 2006;25:943-945.